These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

641 related items for PubMed ID: 32316070

  • 1. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K, IXORA-PEDS study group.
    Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
    [Abstract] [Full Text] [Related]

  • 2. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA, Leonardi CL, Blauvelt A, Reich K, Korman NJ, Ohtsuki M, Paul C, Ball S, Cameron GS, Erickson J, Zhang L, Mallbris L, Griffiths CEM.
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [Abstract] [Full Text] [Related]

  • 3. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA, IXORA-PEDS Investigators.
    JAMA Dermatol; 2022 May 01; 158(5):533-541. PubMed ID: 35416908
    [Abstract] [Full Text] [Related]

  • 4. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group.
    Br J Dermatol; 2020 Jun 01; 182(6):1348-1358. PubMed ID: 31887225
    [Abstract] [Full Text] [Related]

  • 5. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):477-482. PubMed ID: 27910156
    [Abstract] [Full Text] [Related]

  • 6. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C.
    J Eur Acad Dermatol Venereol; 2017 Jul 01; 31(7):1196-1207. PubMed ID: 28370467
    [Abstract] [Full Text] [Related]

  • 7. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
    Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, Lomaga M, Dutronc Y, Henneges C, Wilhelm S, Hartz S, Paul C, IXORA-S investigators.
    Br J Dermatol; 2017 Oct 01; 177(4):1014-1023. PubMed ID: 28542874
    [Abstract] [Full Text] [Related]

  • 8. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
    Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C.
    J Eur Acad Dermatol Venereol; 2020 Feb 01; 34(2):301-309. PubMed ID: 31479549
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
    Blauvelt A, Kimball AB, Augustin M, Okubo Y, Witte MM, Capriles CR, Sontag A, Arora V, Osuntokun O, Strober B.
    Br J Dermatol; 2022 Dec 01; 187(6):866-877. PubMed ID: 35791755
    [Abstract] [Full Text] [Related]

  • 10. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

  • 11. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, Erickson J, Zhang L, Mallbris L, Gerdes S.
    J Eur Acad Dermatol Venereol; 2017 Apr 08; 31(4):679-685. PubMed ID: 27696577
    [Abstract] [Full Text] [Related]

  • 12. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 08; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).
    Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K.
    J Eur Acad Dermatol Venereol; 2017 Oct 08; 31(10):1686-1692. PubMed ID: 28322474
    [Abstract] [Full Text] [Related]

  • 14. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
    Papp K, Maari C, Cauthen A, Gooderham M, Spelman L, Yamanaka K, Polzer P, Zhang L, Osuntokun O, Augustin M.
    Br J Dermatol; 2020 Jul 08; 183(1):52-59. PubMed ID: 31545506
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.
    Am J Clin Dermatol; 2017 Apr 08; 18(2):273-280. PubMed ID: 28074446
    [Abstract] [Full Text] [Related]

  • 16. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, Ball S, Mallbris L, Gonzalez P, Fernández-Peñas P, Puig L.
    J Am Acad Dermatol; 2018 Nov 08; 79(5):824-830.e2. PubMed ID: 29803904
    [Abstract] [Full Text] [Related]

  • 17. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H.
    J Dermatolog Treat; 2017 Jun 08; 28(4):282-287. PubMed ID: 27759463
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
    Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A, IXORA-Q Study Group.
    Br J Dermatol; 2018 Oct 08; 179(4):844-852. PubMed ID: 29747232
    [Abstract] [Full Text] [Related]

  • 19. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
    Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A.
    J Dermatolog Treat; 2020 Mar 08; 31(2):141-146. PubMed ID: 30799638
    [Abstract] [Full Text] [Related]

  • 20. Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.
    Cather JC, Young CT, Young MS, Cather JC.
    Expert Opin Biol Ther; 2021 Aug 08; 21(8):983-990. PubMed ID: 34106794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.